Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zanvipixant SCHEMBL31347780 | 1.00 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| Zanvipixant SCHEMBL16035842 | 1.00 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| Zanvipixant SCHEMBL16035844 | 1.00 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL16127677 | 0.94 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL17509159 | 0.94 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL31567839 | 0.93 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL16089637 | 0.92 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL29689577 | 0.92 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL16036929 | 0.92 | P2RX7 (1.00) | P2RX7CYP2C19 | |
| SCHEMBL16036926 | 0.92 | P2RX7 (1.00) | P2RX7CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367144-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-12-04 | — | — | US | disclosed |
| US-12419848-B2 | Treatment of hyperinflammatory syndrome | Remicine IP B.V. (NL) | 2025-09-23 | — | — | US | disclosed |
| EP-4582147-A2 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Remicine IP B.V. (NL) | 2025-07-09 | — | — | EP | disclosed |
| US-20250195855-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2025-06-19 | — | — | US | disclosed |
| EP-4125843-B1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-05-21 | — | — | EP | disclosed |
| EP-4493258-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119173296-A | Ingestible devices for delivering therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023178354-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230128348-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Remicine IP B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| EP-4125843-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Nomoreitis B.V. (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115605194-A | Treatment of excessive inflammatory syndrome | 诺莫雷蒂斯私人有限公司（BE） | 2023-01-13 | — | — | CN | disclosed |
| US-20220326258-A1 | BIOMARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND MOTOR NEURON DISEASES | NORTHWESTERN UNIVERSITY | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | P2RX7 1356/4885CYP2C19 2728/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | P2RX7 1356/4885CYP2C19 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.